Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 10, 2024VaccineOpen Access

A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

VTVũ Đình ThiểmPAPham Thi Van AnhCMChu Van Men

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Thiểm et al. (2024) studied this question.

synapsesocial.com/papers/68e6ab1eb6db64358762d3f4https://doi.org/10.1016/j.vaccine.2024.04.084
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine2020 · 10,914 citations
  2. 2COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.2021 · 584 citations
  3. 3Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant2022 · 2,273 citations
  4. 4The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors2015 · 256 citations
  5. 5Nonparametric Estimation from Incomplete Observations1958 · 39,519 citations